ASH 2023 | Exciting developments in the field of BPDCN
In this video, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses exciting developments being made in the field of blastic plasmacytoid dendritic cell neoplasm (BPDCN), highlighting novel agents being explored, namely pivekimab sunirine, and the promise of combination therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So blastic plasmacytoid dendritic cell neoplasm, or BPDCN, remains one of the most important areas of my own team’s research. As many of you may remember, we were able to lead the first and only FDA approved drug in that space tagraxofusp exactly five years ago. But since then, we’ve made three separate developments that I’d like to share with you, some of them were featured here at ASH...
So blastic plasmacytoid dendritic cell neoplasm, or BPDCN, remains one of the most important areas of my own team’s research. As many of you may remember, we were able to lead the first and only FDA approved drug in that space tagraxofusp exactly five years ago. But since then, we’ve made three separate developments that I’d like to share with you, some of them were featured here at ASH.
Number one is that we are working on a second drug now called IMGN632 or pivekimab sunirine, and we presented those results in the EHA meeting in the summer of 2023. So it’s a second generation or next generation CD123, a different payload. And that’s showing activity and safety in BPDCN with those results ongoing.
The second aspect of BPDCN is investigating combination therapies. So combining the TAG with AZA and VEN, as we’re doing in AML, so doing that also in BPDCN. Or with chemotherapy, so the TAG/hyper-CVAD/VEN program that I have open exclusively at MD Anderson at my site. So those are for BPDCN specific.
And then the third aspect that I think is exciting is understanding the molecular or biological understanding of BPDCN, and that we have our scientists across the world working together to try to understand and unravel the basic components of BPDCN.
Read more...
Disclosures
Consultancy: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals
Membership on Board of Directors/Advisory Committees: ClearView Healthcare Partners, Imedex, Protagonist Therapeutics Inc., EUSA Pharma, Curio Science, Dan’s House of Hope, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Stemline, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals
Speakers Bureau: ClearView Healthcare Partners, Imedex, EUSA Pharma, Curio Science, CareDx, Harborside Press, Dava Oncology, CancerNet, Aplastic Anemia & MDS International Foundation, Pacylex, Patient Power, Menarini Group, Astellas, BMS, PeerView Institute for Medical Education, Medscape, OncLive, Physician Education Resource (PER), Celgene, PharmaEssentia, Novartis Pharmaceuticals:, Magdalen Medical Publishing, Neopharm, Intellisphere, Blueprint, Cimeio Therapeutics AG, ImmunoGen, CTI BioPharma, Incyte, Aptitude Health, AbbVie, Bristol Myers Squibb Pharmaceuticals
Research Funding: United States Department of Defense (DOD), National Institute of Health/National Cancer Institute (NIH/NCI)
Licenses: Karger Publishers
Leadership role on ASH Committee on Communications and ASCO Cancer.Net Editorial Board
